Cargando…
Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment()
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier España, S.L.U.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219577/ https://www.ncbi.nlm.nih.gov/pubmed/35752586 http://dx.doi.org/10.1016/j.reumae.2022.06.001 |
| _version_ | 1784732148943552512 |
|---|---|
| author | Aomar-Millán, Ismael Francisco Salvatierra, Juan Callejas-Rubio, José Luis Raya-Álvarez, Enrique |
| author_facet | Aomar-Millán, Ismael Francisco Salvatierra, Juan Callejas-Rubio, José Luis Raya-Álvarez, Enrique |
| author_sort | Aomar-Millán, Ismael Francisco |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9219577 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Published by Elsevier España, S.L.U. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92195772022-06-23 Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment() Aomar-Millán, Ismael Francisco Salvatierra, Juan Callejas-Rubio, José Luis Raya-Álvarez, Enrique Reumatol Clin (Engl Ed) Letter to the Editor Published by Elsevier España, S.L.U. 2023-02 2022-06-22 /pmc/articles/PMC9219577/ /pubmed/35752586 http://dx.doi.org/10.1016/j.reumae.2022.06.001 Text en © 2022 Published by Elsevier España, S.L.U. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Letter to the Editor Aomar-Millán, Ismael Francisco Salvatierra, Juan Callejas-Rubio, José Luis Raya-Álvarez, Enrique Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment() |
| title | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment() |
| title_full | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment() |
| title_fullStr | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment() |
| title_full_unstemmed | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment() |
| title_short | Anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with SARS-CoV-2 refractory to tocilizumab: comment() |
| title_sort | anakinra as a potential alternative in the treatment of severe acute respiratory infection associated with sars-cov-2 refractory to tocilizumab: comment() |
| topic | Letter to the Editor |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9219577/ https://www.ncbi.nlm.nih.gov/pubmed/35752586 http://dx.doi.org/10.1016/j.reumae.2022.06.001 |
| work_keys_str_mv | AT aomarmillanismaelfrancisco anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumabcomment AT salvatierrajuan anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumabcomment AT callejasrubiojoseluis anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumabcomment AT rayaalvarezenrique anakinraasapotentialalternativeinthetreatmentofsevereacuterespiratoryinfectionassociatedwithsarscov2refractorytotocilizumabcomment |